Format

Send to

Choose Destination
Gynecol Endocrinol. 2008 Mar;24(3):139-44. doi: 10.1080/09513590801893232.

Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.

Author information

1
Department of Obstetrics and Gynecology, University of Modena and Reggio Emilia, Italy. algen@unimore.it

Abstract

OBJECTIVE:

To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of PCOS patients.

DESIGN:

Controlled clinical study.

SETTING:

PCOS patients in a clinical research environment.

PATIENTS:

20 overweight PCOS patients were enrolled after informed consent.

INTERVENTIONS:

All patients underwent hormonal evaluations and an oral glucose tollerance test (OGTT) before and after 12 weeks of therapy (Group A (n = 10): myo-inositol 2 gr. plus folic acid 200 mug every day; Group B (n = 10): folic acid 200 mug every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.

MAIN OUTCOME MEASURES:

Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.

RESULTS:

After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.

CONCLUSIONS:

Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.

PMID:
18335328
DOI:
10.1080/09513590801893232
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center